Open Access

Protein components of maple syrup as a potential resource for the development of novel anti‑colorectal cancer drugs

  • Authors:
    • Tetsushi Yamamoto
    • Ryota Shiburo
    • Yoshie Moriyama
    • Kuniko Mitamura
    • Atsushi Taga
  • View Affiliations

  • Published online on: August 17, 2023     https://doi.org/10.3892/or.2023.8616
  • Article Number: 179
  • Copyright: © Yamamoto et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Maple syrup is a natural sweetener consumed worldwide. Active ingredients of maple syrup possess antitumor effects; however, these ingredients are phenolic compounds. The present study aimed to investigate components other than phenolic compounds that may have antitumor effects against colorectal cancer (CRC). Cell proliferation assays demonstrated that treatment with the more than 10,000 molecular weight fraction significantly inhibited viability in DLD‑1 cells. Therefore, we hypothesized that the protein components of maple syrup may be the active ingredients in maple syrup. We obtained protein components from maple syrup by ammonium sulfate precipitation, and treatment with the protein fraction of maple syrup (MSpf) was found to exhibit a potential antitumor effect. MSpf‑treated DLD‑1 colon adenocarcinoma cells exhibited significantly decreased proliferation, migration and invasion. In addition, upregulation of LC3A and E‑cadherin and downregulation of MMP‑9 expression levels were observed following MSpf treatment. Investigation of the components of MSpf suggested that it was primarily formed of advanced glycation end products (AGEs). Therefore, whether AGEs in MSpf affected the STAT3 pathway through the binding to its receptor, receptor of AGE (RAGE), was assessed. MSpf treatment was associated with decreased RAGE expression and STAT3 phosphorylation. Finally, to determine whether autophagy contributed to the inhibitory effect of cell proliferation following MSpf treatment, the effect of MSpf treatment on autophagy induction following bafilomycin A1 treatment, a specific autophagy inhibitor, was assessed. The inhibitory effect of MSpf treatment on cell proliferation was enhanced through the inhibition of autophagy by bafilomycin A1 treatment. These results suggested that AGEs in MSpf suppressed cell proliferation and epithelial‑mesenchymal transition through inhibition of the STAT3 signaling pathway through decreased RAGE expression. Therefore, AGEs in MSpf may be potential compounds for the development of antitumor drugs for the treatment of CRC with fewer adverse effects compared with existing antitumor drugs.
View Figures
View References

Related Articles

Journal Cover

October-2023
Volume 50 Issue 4

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Yamamoto T, Shiburo R, Moriyama Y, Mitamura K and Taga A: Protein components of maple syrup as a potential resource for the development of novel anti‑colorectal cancer drugs. Oncol Rep 50: 179, 2023.
APA
Yamamoto, T., Shiburo, R., Moriyama, Y., Mitamura, K., & Taga, A. (2023). Protein components of maple syrup as a potential resource for the development of novel anti‑colorectal cancer drugs. Oncology Reports, 50, 179. https://doi.org/10.3892/or.2023.8616
MLA
Yamamoto, T., Shiburo, R., Moriyama, Y., Mitamura, K., Taga, A."Protein components of maple syrup as a potential resource for the development of novel anti‑colorectal cancer drugs". Oncology Reports 50.4 (2023): 179.
Chicago
Yamamoto, T., Shiburo, R., Moriyama, Y., Mitamura, K., Taga, A."Protein components of maple syrup as a potential resource for the development of novel anti‑colorectal cancer drugs". Oncology Reports 50, no. 4 (2023): 179. https://doi.org/10.3892/or.2023.8616